BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 30456447)

  • 1. Cemiplimab: First Global Approval.
    Markham A; Duggan S
    Drugs; 2018 Nov; 78(17):1841-1846. PubMed ID: 30456447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cemiplimab in advanced cutaneous squamous cell carcinoma.
    Naik PP
    Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
    Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214
    [No Abstract]   [Full Text] [Related]  

  • 4. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
    Ahmed SR; Petersen E; Patel R; Migden MR
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
    [No Abstract]   [Full Text] [Related]  

  • 5. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.
    Lee A; Duggan S; Deeks ED
    Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma.
    Patel R; Chang ALS
    Am J Clin Dermatol; 2019 Aug; 20(4):477-482. PubMed ID: 30737731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
    Lebas E; Marchal N; Rorive A; Nikkels AF
    Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
    Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
    Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
    Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RF-Cemiplimab: First Drug Approved for the Treatment of Metastatic or Unresectable Cutaneous Squamous Cell Carcinoma.
    Morgado-Carrasco D; Bosch-Amate X; Fustà-Novell X; Giavedoni P
    Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):161-163. PubMed ID: 31874704
    [No Abstract]   [Full Text] [Related]  

  • 11. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
    Sezer A; Kilickap S; Gümüş M; Bondarenko I; Özgüroğlu M; Gogishvili M; Turk HM; Cicin I; Bentsion D; Gladkov O; Clingan P; Sriuranpong V; Rizvi N; Gao B; Li S; Lee S; McGuire K; Chen CI; Makharadze T; Paydas S; Nechaeva M; Seebach F; Weinreich DM; Yancopoulos GD; Gullo G; Lowy I; Rietschel P
    Lancet; 2021 Feb; 397(10274):592-604. PubMed ID: 33581821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
    Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG
    N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab.
    Stevenson ML; Wang CQ; Abikhair M; Roudiani N; Felsen D; Krueger JG; Pavlick AC; Carucci JA
    JAMA Dermatol; 2017 Apr; 153(4):299-303. PubMed ID: 28259107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
    Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
    Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma.
    Hanania HL; Lewis DJ
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):237-238. PubMed ID: 34918605
    [No Abstract]   [Full Text] [Related]  

  • 16. Dostarlimab: First Approval.
    Markham A
    Drugs; 2021 Jul; 81(10):1213-1219. PubMed ID: 34106455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation.
    Ali SA; Arman HE; Patel AA; Birhiray RE
    JCO Oncol Pract; 2020 Mar; 16(3):137-138. PubMed ID: 31770056
    [No Abstract]   [Full Text] [Related]  

  • 18. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
    Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
    Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First Drug Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma.
    Aschenbrenner DS
    Am J Nurs; 2019 Jan; 119(1):27. PubMed ID: 30589700
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.